Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 9/20 | 0.48 |
| ▸ | SIRT1 | Q96EB6 | 9/20 | 0.48 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | EP300 | Q09472 | 1/20 | 0.43 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.43 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.41 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13167107 | 0.94 | SIRT1 (0.44) | SIRT2SIRT1SIRT3HDAC4EP300 | |
| SCHEMBL2607891 | 0.87 | SIRT1 (0.44) | SIRT2SIRT1SIRT3HDAC4EP300 | |
| SCHEMBL12583936 | 0.87 | SIRT1 (0.47) | SIRT2SIRT1SIRT3HDAC4EP300 | |
| SCHEMBL12410205 | 0.87 | SIRT1 (0.49) | SIRT2SIRT1SIRT3HDAC4EP300 | |
| SCHEMBL25176589 | 0.86 | KMT2A (0.45) | SIRT2SIRT1SIRT3 | |
| SCHEMBL25176590 | 0.86 | KMT2A (0.45) | SIRT2SIRT1SIRT3 | |
| SCHEMBL15975505 | 0.86 | TGM2 (0.48) | SIRT2SIRT1SIRT3 | |
| SCHEMBL11955678 | 0.85 | SIRT2 (0.42) | SIRT2SIRT1SIRT3SIRT6 | |
| SCHEMBL13932138 | 0.85 | ACHE (0.44) | SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL17851524 | 0.84 | SIRT1 (0.40) | SIRT2SIRT1SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682153-B2 | Polymer conjugates of therapeutic peptides | NEKTAR THERAPEUTICS (US) | 2017-06-20 | — | — | US | disclosed |
| US-20170035896-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS | 2017-02-09 | — | — | US | disclosed |
| US-20170035898-A1 | CONJUGATES OF AN IL-15 MOIETY AND A POLYMER | NEKTAR THERAPEUTICS | 2017-02-09 | — | — | US | disclosed |
| US-9446139-B2 | Polymer-based compositions and conjugates of HIV entry inhibitors | NEKTAR THERAPEUTICS (US) | 2016-09-20 | — | — | US | disclosed |
| US-9433684-B2 | Conjugates of small-interfering nucleic acids | NEKTAR THERAPEUTICS (US) | 2016-09-06 | — | — | US | disclosed |
| US-9421275-B2 | Oligomer-calcimimetic conjugates and related compunds | NEKTAR THERAPEUTICS (US) | 2016-08-23 | — | — | US | disclosed |
| US-9347054-B2 | Polymer factor IX moiety conjugates | NEKTAR THERAPEUTICS (US) | 2016-05-24 | — | — | US | disclosed |
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS | 2016-01-28 | — | — | US | disclosed |
| US-9101670-B2 | Conjugates of an anti-TNF-α antibody | NEKTAR THERAPEUTICS (US) | 2015-08-11 | — | — | US | disclosed |
| US-20150038422-A1 | UNIT DOSAGE FORMS OF PHARMACEUTICAL COMPOSITIONS COMPRISING A POLYMER-FACTOR VIII POLYPEPTIDE CONJUGATE | NEKTAR THERAPEUTICS | 2015-02-05 | — | — | US | disclosed |
| US-20100120689-A1 | POLYMER FACTOR VIII MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120982-A1 | POLYMER-FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-13 | — | — | US | disclosed |
| US-7714114-B2 | Conjugates of an EPO moiety and a polymer | NEKTAR THERAPEUTICS (US) | 2010-05-11 | — | — | US | disclosed |
| US-20100021481-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | NEKTAR THERAPEUTICS (US) | 2010-01-28 | — | — | US | disclosed |
| US-20090280550-A1 | Polymer-Factor IX Moiety Conjugates | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| US-7579444-B2 | Polymer-factor IX moiety conjugates | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090041714-A1 | Binding element comprising polyethylene glycol and antihemophilic factor for use in treatment of hemophilia | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-02-12 | — | — | US | disclosed |
| US-20080058504-A1 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | NEKTAR THERAPEUTICS | 2008-03-06 | — | — | US | disclosed |
| US-20070092482-A1 | Conjugates of a G-CSF moiety and a polymer | NEKTAR THERAPEUTICS | 2007-04-26 | — | — | US | disclosed |
| US-7199223-B2 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2007-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038422-A1 | UNIT DOSAGE FORMS OF PHARMACEUTICAL COMPOSITIONS COMPRISING A POLYMER-FACTOR VIII POLYPEPTIDE CONJUGATE | F8, F13B, F13A1 | SIRT2 4418/4885SIRT1 4430/4885SIRT3 4610/4885 |
| US-20090041714-A1 | Binding element comprising polyethylene glycol and antihemophilic factor for use in treatment of hemophilia | F13B, F8, F13A1 | SIRT2 4529/4885SIRT1 4665/4885SIRT3 4712/4885 |
| US-20100120689-A1 | POLYMER FACTOR VIII MOIETY CONJUGATES | F8, F9, F13B | SIRT2 4221/4885SIRT1 4441/4885SIRT3 4538/4885 |
| US-20170035896-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | F9, F13A1, F8 | SIRT2 4162/4885SIRT1 3966/4885SIRT3 4065/4885 |
| US-20100120982-A1 | POLYMER-FACTOR IX MOIETY CONJUGATES | F9, F13A1, F13B | SIRT2 4080/4885SIRT1 3908/4885SIRT3 4065/4885 |
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | SIRT2 3408/4885SIRT1 3118/4885SIRT3 2996/4885 |
| US-20100021481-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | TNF, TNFRSF1A, TNFRSF9 | SIRT2 4104/4885SIRT1 3698/4885SIRT3 4588/4885 |
| US-20070092482-A1 | Conjugates of a G-CSF moiety and a polymer | CSF3R, GMFG, CSF1R | SIRT2 4032/4885SIRT1 3894/4885SIRT3 4145/4885 |
| US-20080058504-A1 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | F8, F13A1, F13B | SIRT2 4490/4885SIRT1 4397/4885SIRT3 4594/4885 |
| US-20170035898-A1 | CONJUGATES OF AN IL-15 MOIETY AND A POLYMER | IL15, IL15RA, IL2 | SIRT2 2813/4885SIRT1 2294/4885SIRT3 2326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.